Tag: bioequivalence standards
- March
9
2026 - 5
FDA Bioequivalence Standards for NTI Drugs: Special Requirements Explained
The FDA requires stricter bioequivalence standards for NTI drugs like warfarin, digoxin, and phenytoin, with tighter limits (90-111%) and scaled testing to ensure patient safety. These rules prevent dangerous variations in generic versions.
Read More- January
24
2026 - 5
Bioequivalence Explained: FDA Requirements to Prove Generic Drug Equivalence
Learn how the FDA uses bioequivalence studies to prove that generic drugs work just like brand-name versions. Understand the 80-125% rule, what it really means, and why generics are safe and effective.
Read More